IDEXX Laboratories, Inc. (IDXX) - Stock Analysis
Last updated: Jan 13, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Selected as a solid growth name with raised 2025 guidance supported by strong diagnostic product adoption and margin expansion; upcoming Nov 3 Q3 earnings represent key catalyst amid moderate technical weakness requiring caution.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠High gross/EBITDA margins ⢠Increasing debt ⢠Elevated valuation multiples Idexx delivers durable high profitability and strong FCF but faces weakening short-term liquidity, rising leverage, and materially stretched valuation multiples as of 2025-09-30.
Price Behavior
Key Price Behavior Insights: ⢠Higher lows ⢠Support bounce ⢠Resistance stall Support Level: $670 Resistance Level: $730â$735 Over last month IDXX recovered from a ~670 support to about $725 but has stalled at the $730â$735 area, signaling an upward bias that's capped near-term.
Sentiment & News
Key News Insights: ⢠Diagnostics momentum ⢠Software adoption ⢠Mixed institutional flows IDEXX has rallied ~65% yearâoverâyear on diagnostics and software momentum, strong retention, ESG credibility and AI-driven product trends, despite mixed institutional flows ahead of its Feb 2, 2026 results.
AI Summary
IDEXX is shifting from a consumablesâled cash machine to a capitalâintensive diagnostics+software recurringârevenue model, so its rich valuation is now explicitly contingent on executing InVue instrument placements and converting software into material ARR. Watch Q4/FY placements, software ARR cadence, and cash/debt trends closelyâbeats would validate the multiple, while missed placements, sustained visit weakness, or worsening liquidity would quickly compress valuation.
Description
IDEXX Laboratories develops, manufactures, and sells diagnostic instruments, consumables, laboratory services, and practice management software for veterinary, livestock, dairy and water-testing markets worldwide. Its offerings include point-of-care and reference laboratory diagnostics, imaging and monitoring systems, and microbiological water tests, supported by sales, technical service teams and distribution partners. The company also supplies certain human point-of-care analyzers; it was founded in 1983 and is headquartered in Westbrook, Maine.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Nov 3 | Nov 10 | IDXX | IDEXX Laboratories, Inc. | Selected as a solid growth name with raised 2025 guidance supported by strong diagnostic product adoption and margin expansion; upcoming Nov 3 Q3 earnings represent key catalyst amid moderate technical weakness requiring caution. | Closed | -1.8% |